Ole Andreas Halvorsen
Viking Global Investors
Ole Andreas Halvorsen BIOHAVEN PHARMACEUTICAL HOLD stake
total: 670
Viking Global Investors BHVN-OLD trades
- Total transactions:
- 3
- New positions:
- 1
- Sold out:
- 1
- Added:
- 1
- Held since:
- 2021 Q4
- Held for:
- 2 quarters
- Latest activity:
- 2022 Q2
According to 2026 Q2 report, Ole Andreas Halvorsen doesn't hold any BIOHAVEN PHARMACEUTICAL HOLD (BHVN-OLD) shares. To date, the estimated cost basis is nearly $125.52 for "buy" trades and estimated average "sell" price is $118.57. Viking Global Investors first purchased BHVN-OLD in 2021 Q4, initially acquiring 348,783 shares. Since the initial investment in BIOHAVEN PHARMACEUTICAL HOLD (BHVN-OLD), Viking Global Investors has made 2 more transactions.
When did Ole Andreas Halvorsen sell BIOHAVEN PHARMACEUTICAL HOLD (BHVN-OLD)?
Ole Andreas Halvorsen sold off the entire BIOHAVEN PHARMACEUTICAL HOLD (BHVN-OLD) position in 2022 Q2.
When did Ole Andreas Halvorsen buy BIOHAVEN PHARMACEUTICAL HOLD (BHVN-OLD)?
Ole Andreas Halvorsen first invested in BIOHAVEN PHARMACEUTICAL HOLD (BHVN-OLD) in 2021 Q4 at the reported quarter-end price of $137.81 per share.
What's the cost basis of Viking Global Investors's BHVN-OLD stake?
The estimated cost basis for BIOHAVEN PHARMACEUTICAL HOLD (BHVN-OLD) stake is around $125.52 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $125.52
- Weighted AVG sell price:
- $118.57
Ole Andreas Halvorsen's historical trades in BIOHAVEN PHARMACEUTICAL HOLD
3 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2022 Q2
|
0.00%
|
0
|
$118.57
|
|
-100% (-966,139)
|
-0.46%
|
|
2022 Q1
|
0.46%
|
966,139
|
$118.57
|
$114,555,000
|
+177.00% (+617,356)
|
+0.3%
|
|
2021 Q4
|
0.14%
|
348,783
|
$137.81
|
$48,066,000
|
new
|
+0.14%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.